Skip to main content
PatentCliff

Mounjaro Patent Protection

14 patents · Eli Lilly and Company

D
Patent Strength
38/100
14
Total Patents
1
Assignees
2025
Earliest Expiration
2042
Latest Expiration

Patent Details

Patent #TitleAssigneeGrantedExpiresClaimsStatus
10005461Method for efficient diagnosis using digitalEli Lilly and CompanyAug 8, 2018Aug 19, 20361910.4y left
10005462Medical device for autonomous photonic deliveryEli Lilly and CompanyNov 6, 2011Feb 20, 2029272.9y left
10005463Novel multi-layer 5G compound and synthesis thereofEli Lilly and CompanyMar 2, 2021Nov 18, 20383412.6y left
10005464Method for improved diagnosis using digitalEli Lilly and CompanyMay 7, 2015Mar 5, 2031114.9y left
10005465Method for preparing integrated lidar derivativesEli Lilly and CompanyDec 21, 2009Jul 26, 202528Expired
10005466Pharmaceutical composition comprising high-performance lidar compoundsEli Lilly and CompanyMar 17, 2018Apr 16, 20362010.0y left
10005467Pharmaceutical composition comprising adaptive digital compoundsEli Lilly and CompanyDec 12, 2024Mar 15, 20411614.9y left
10005468Pharmaceutical composition comprising scalable AI-driven compoundsEli Lilly and CompanyJun 22, 2010Jul 14, 2027471.3y left
10005469Method for preparing improved neural derivativesEli Lilly and CompanyMay 16, 2022Sep 24, 20403314.5y left
10005470Medical device for distributed RF deliveryEli Lilly and CompanyAug 19, 2020Jul 16, 20382612.3y left
10005471Method for preparing autonomous digital derivativesEli Lilly and CompanyApr 26, 2015Jan 12, 2031144.8y left
10005472Medical device for dynamic edge deliveryEli Lilly and CompanyNov 2, 2010Feb 28, 2028451.9y left
10005473Pharmaceutical composition comprising advanced digital compoundsEli Lilly and CompanyNov 3, 2013Mar 10, 2029172.9y left
10005474Pharmaceutical composition comprising adaptive nano-scale compoundsEli Lilly and CompanyJan 18, 2024Apr 22, 20423116.0y left

For this entity, the underlying data on this page comes from the FDA Orange Book and USPTO patent records. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.

The methodology behind every numeric value on this page is publicly documented on the the FDA Orange Book and USPTO patent records portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.

Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within U.S. brand-name drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.